● 刘英杰 谭丁豪 近期，在政策、业绩等多因素推动下，人工智能端侧应用再次引起市场关注。Wind数据显示，万得人 工智能概念指数自4月8日以来上涨13.44%。 分析人士认为，DeepSeek的爆火正在推动大模型行业向开源+降本的趋势发展，将有望加速AI应用的商 用化。随着终端芯片算力提升与轻量化模型优化，人工智能端侧正从技术概念走向规模化应用，相关产 业链投资机会值得重视。 利好因素不断催化 日前，人工智能终端产业发展研讨会在北京召开，工业和信息化部副部长熊继军在研讨会上表示，人工 智能终端是人工智能技术落地应用的关键载体。要加强部门联动和产业协同，以人工智能终端工作组为 桥梁纽带，统筹开展技术创新、标准研究、应用推广、生态建设等工作。要加大高质量产品供给，加快 人工智能技术在各类消费终端的普及落地。 在研讨会上，人工智能终端基准和智能化分级计划正式启动，将由人工智能终端工作组联合全国信标委 人工智能分委会、全国音视频及多媒体系统与设备标委会下设的人工智能终端标准组共同推动各类人工 智能终端评价方法落地实施，形成行业共识，支撑相关政策落地。 产品端，2025年一季度，Edge AI（人工智能端侧）芯片迎来存 ...

Diluted earnings per share (“EPS”) of $1.69 and Adjusted EPS of $1.90BOSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Cabot Corporation (NYSE: CBT) today announced results for its second quarter of fiscal year 2025. Key Highlights Diluted EPS of $1.69 and Adjusted EPS of $1.90 which represents a 7% increase in Adjusted EPS compared to the same quarter in the prior year Reinforcement Materials segment EBIT of $131 million; up 1% sequentially; down 12% compared to the same quarter in the prior year Performance Chemi ...

Delivers lower-than-expected sales amid a challenging and volatile consumer and geopolitical environment while maintaining overall market shares and delivering its 10th consecutive quarter of gross margin expansionOAKLAND, Calif., May 5, 2025 /PRNewswire/ -- The Clorox Company (NYSE: CLX) today reported results for the third quarter of fiscal year 2025, which ended Mar. 31, 2025.Third-Quarter Fiscal Year 2025 SummaryFollowing is a summary of key results for the third quarter, which reflect the prior divesti ...

截至2025年4月30日收盘，星湖科技(600866)报收于7.56元，下跌1.05%，换手率3.45%，成交量38.24万 手，成交额2.92亿元。 董秘最新回复 投资者： 去年请问出口美国收入多少？ 董秘： 尊敬的投资者，您好！在国际市场上，公司产品远销欧洲、东南亚、韩国等50多个国家与地 区，公司2024年度国外整体销售收入情况请详见公司于2025年4月22日在上海证券交易所披露的临2025- 011号《2024年度主要经营数据公告》。感谢您的关注！ 投资者： 请问，截止4月25日收盘，股东户数多少？ 董秘： 尊敬的投资者，您好！关于公司的股东户数请详见公司于2025年4月22日在上海证券交易所披露 的《2025年第一季度报告》，感谢您的关注！ 投资者： 董秘您好，根据美国对中国的最新关税政策，对公司影响有多大，是否可以进行成本转移， 公司对美国出口的营业收入占比有多少，未来对美业务规划如何。 董秘： 尊敬的投资者，您好！在国际市场上，公司产品远销欧洲、东南亚、韩国等50多个国家与地 区，目前美国对中国的关税政策不会对公司的生产经营产生重大影响。公司将密切关注国际经济环境及 相关政策的变化，积极研究和制 ...

For the quarter ended March 2025, RLJ Lodging (RLJ) reported revenue of $328.12 million, up 1.1% over the same period last year. EPS came in at $0.31, compared to -$0.01 in the year-ago quarter.The reported revenue represents a surprise of -0.34% over the Zacks Consensus Estimate of $329.24 million. With the consensus EPS estimate being $0.30, the EPS surprise was +3.33%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine the ...

伯克希尔哈撒韦B(BRK.B.N)Q1 EPS为2.13美元，上年同期5.88美元。 ...

Core Insights - CBOE Global reported revenue of $565.2 million for Q1 2025, a 12.6% year-over-year increase, with EPS of $2.50 compared to $2.15 a year ago, exceeding Zacks Consensus Estimates [1] - The company achieved a revenue surprise of +1.54% and an EPS surprise of +5.93% compared to analyst expectations [1] Financial Performance Metrics - Average Revenue Per Contract for Futures was $1.74, slightly below the $1.76 estimate [4] - Average Daily Volume for Multi-listed options was 13.41 million, exceeding the 12.99 million estimate [4] - Access and capacity fees generated $97.80 million, surpassing the $96.55 million estimate, reflecting an 8.6% year-over-year increase [4] - Market data fees totaled $77.80 million, above the $75.92 million estimate, with an 8.1% year-over-year increase [4] - Other revenue was $25 million, below the $28.23 million estimate, representing a -5.3% change year-over-year [4] - Net transaction and clearing fees reached $832.60 million, exceeding the $788.83 million estimate, with a 15.9% year-over-year increase [4] - Regulatory fees surged to $161.80 million, significantly above the $90.18 million estimate, marking a 222.3% year-over-year increase [4] Stock Performance - CBOE shares returned -2% over the past month, compared to a -0.5% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential outperformance in the near term [3]

Cigna (CI) reported $65.45 billion in revenue for the quarter ended March 2025, representing a year-over-year increase of 14.3%. EPS of $6.74 for the same period compares to $6.47 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $60.8 billion, representing a surprise of +7.66%. The company delivered an EPS surprise of +5.48%, with the consensus EPS estimate being $6.39.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they ...

On track for six major study readouts across four programs over the next 12 months Ready to initiate pivotal studies in two developmental and epileptic encephalopathy (DEE) programs in mid-year 2025: EMERALD for broad DEEs with relutrigine and EMBRAVE3 for SCN2A GoF with elsunersen Vormatrigine continues to generate a best-in-class safety profile with new data demonstrating no food effect and higher dosing tolerability Praxis to host a virtual investor event on Friday, May 2, 2025 to discuss its DEE portfol ...

Group 1 - Cardinal Health Inc. reported third-quarter 2025 adjusted EPS of $2.35, a 13% increase year over year, surpassing the consensus estimate of $2.17 [1] - Sales remained flat at $54.9 billion, missing the consensus of $55.35 billion, while adjusted operating earnings increased by 21% to $807 million [1] - The Pharmaceutical and Specialty Solutions segment's sales were unchanged at $50.6 billion [1] Group 2 - Revenue for the Global Medical Products and Distribution (GMPD) segment rose by 2% to $3.2 billion, driven by volume growth from existing customers [2] - Segment profit increased by 14% to $662 million in the third quarter, supported by brand and specialty products, MSO platforms, and positive generics program performance [6] - The company raised its fiscal year 2025 adjusted EPS guidance from $7.85-$8.00 to $8.05-$8.15, compared to the consensus of $7.96 [3] Group 3 - Cardinal Health anticipates double-digit non-GAAP EPS growth in fiscal 2026 despite evolving macroeconomic conditions [4] - The outlook for the Pharmaceutical and Specialty Solutions segment profit was increased to 11.5% to 12.5% growth, up from a previous range of 10% to 12% [6] - The company expects GMPD segment profit to be consistent with fiscal 2025 segment profit amid macro uncertainty [6] Group 4 - CAH stock is trading 2.30% higher at $144.53 [5] - The company plans to discuss its fiscal 2026 and beyond expectations at its upcoming Investor Day on June 12 [6]